PROGNOSTIC IMPLICATIONS OF CMV INFECTION/DISEASE AND HHV-6 ENCEPHALITIS IN CORD BLOOD TRANSPLANT RECIPIENTS RECEIVING FOSCARNET (EBMT 2026) - Mar 14, 2026 - Abstract #B081; Pres time: Mar 24, 2026; 06:00 PM - 07:00 PM; Location: VELAZQUEZ; "Prophylactic administration of letermovir was not performed. Tacrolimus and mycophenolate mofetil were used for GVHD prophylaxis.Primary endpoints were the cumulative incidence of CMV infection and its impact on relapse, non-relapse mortality (NRM), and overall survival (OS)... In CBT with prophylactic FOS, CMV infection was associated with higher NRM, with CMV disease showing a more pronounced impact and adversely affecting OS. Although prophylactic FOS did not sufficiently prevent HHV-6 encephalitis, its occurrence did not affect outcomes."
Clinical • Acute Graft versus Host Disease • CNS Disorders • Cytomegalovirus Infection • Epstein-Barr Virus Infections • Gastroenterology • Gastrointestinal Disorder • Graft versus Host Disease • Immunology • Infectious Disease • Nephrology • Pneumonia • Respiratory Diseases • Transplantation
|
|
Shogo Matsui1; Hisashi Yamamoto1; Mika Kuno1; Otoya Watanabe1; Kyosuke Yamaguchi2; Kosei Kageyama2; Daisuke Kaji1; Yuki Taya2; Aya Nishida1; Shinsuke Takagi1; Yuki Mori1; Go Yamamoto1; Atsushi Wake2; Shuichi Taniguchi1; Naoyuki Uchida1
|